Cancer development and its response to therapy are regulated by inflammation, which
either promotes or suppresses tumor progression, potentially displaying opposing effects on …

The immune-related adverse events associated with treatment with immune checkpoint
inhibitors result in significant morbidity for patients as well as considerable cost to the health …

Immune checkpoint inhibitors (ICIs) are the standard of care for the treatment of several
cancers. While these immunotherapies have improved patient outcomes in many clinical …

Cancer immunotherapies, including checkpoint inhibitors and adoptive cell therapy,
manipulate the immune system to recognize and attack cancer cells. These therapies have …

Side Effects of Immune Checkpoint Blockade The wide range of immune-related adverse
effects associated with immune checkpoint blockade can complicate this effective therapy …

Immunotherapy with monoclonal antibodies (MoAbs) targeting cytotoxic T lymphocyte-
associated antigen 4 (CTLA4) and the programmed death-1 receptor (PD-1) and its ligand …

Immune checkpoints are small molecules expressed by immune cells that play critical roles
in maintaining immune homeostasis. Targeting the immune checkpoints cytotoxic T …

The recent success of PD-1 and PD-L1 blockade in cancer therapy illustrates the important
role of the PD-1/PD-L1 pathway in the regulation of antitumor immune responses. However …

The aim of the NCCN Guidelines for Management of Immunotherapy-Related Toxicities is to
provide guidance on the management of immune-related adverse events resulting from …

Background A number of studies have reported an association between the occurrence of
immune-related adverse events (irAEs) and clinical efficacy in patients undergoing treatment …